Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

ing diseases. In addition to a recently completed Phase IIIb study in malignant mesothelioma, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

ALFACELL CORPORATION

Condensed Statements of Operations

Three-Months Ended Fiscal Year Ended

July 31 July 31

2008 2007 2008
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015  scPharmaceuticals, ... transformative pharmaceutical products for subcutaneous delivery, announced ... trial of its investigational proprietary drug product, ... edema associated with congestive heart failure. ... is developing a proprietary patch pump.  The ...
(Date:4/21/2015)... 2015 Progyny, Inc., the new combined ... that it has secured additional capital from investors including ... One and Merck Serono Ventures. The funding will enable ... best fertility outcomes by aligning science, technology, clinics and ... for families seeking fertility solutions and we are committed ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 YourEncore, ... the life sciences, consumer products and food sciences ... and the Alliance for Clinical Research Excellence and ... system for conducting clinical research, have partnered to ... , YourEncore brings to ACRES experts ...
(Date:4/20/2015)... , April 20, 2015 Orthobiologics ... healing bone injuries. The orthobiologics market is a rewarding ... its stakeholders. The global orthobiologics market report defines and ... revenue. The global orthobiologics market was valued at $5,712.4 ... million by 2019, at a CAGR of 6.7% from ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... technique long used by statisticians to analyze data is ... learning, Alzheimer,s and Parkinson,s diseases and stroke. Researchers ... Science Center at Houston (UTHealth) reported today in the ... fluorescence resonance energy transfer (FRET) techniques combined with wavelet ...
... / PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: ... intended to more closely align its corporate structure ... President Research, will assume responsibility for the entire ... Essentials, Research Specialties and Research Biotech.  This newly ...
... 2011 Chimerix, Inc., a pharmaceutical company developing orally ... awarded a contract by the Biomedical Advanced Research and ... broad spectrum antiviral drug candidate, CMX001, as a medical ... CMX001 is a potential dual-use therapeutic with ...
Cached Biology Technology:Researchers get a grip on nervous system's receptors 2Researchers get a grip on nervous system's receptors 3Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... FLA research team led by Cary Pirone from the ... identified bilirubin in the popular Bird of Paradise plant. ... of the American Society for Horticultural Science,s journal ... this iconic tropical plant. Previously thought to ...
... from door-to-door interviews, Stanford University geographer Eric Lambin and ... rise to a broad range of land-use challenges ... Lyme disease in Belgium. For decades, orbiting satellites ... of the Earth, giving scientists an unprecedented view of ...
... development and successful initial tests on a substance that ... a fungus, brightening prospects for wider use of the ... that attack food crops. "Our finding is especially important ... control treatments like this will help to reduce dependence ...
Cached Biology News:First discovery of bilirubin in a flower announced 2Stanford land-use expert brings satellite data down to Earth 2Stanford land-use expert brings satellite data down to Earth 3Stanford land-use expert brings satellite data down to Earth 4
Request Info...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Biology Products: